ARUP Partners With ELLKAY to Bring Connectivity Solutions to Health System Outreach Operations
A new partnership between ARUP and connectivity provider ELLKAY aims to give health systems the testing support, guidance, and technology needed to establish or expand lab outreach operations.- April 24, 2024
- April 1, 2024
New ARUP University Business Unit Focuses on Patients and Services at University of Utah Health
Dan Albertson, MD, will serve as president of the new University Business Unit and become a member of ARUP’s executive committee. Albertson said service to patients and colleagues will be his focus. - March 5, 2024Nearly 85% of respondents to an ARUP survey believe the FDA’s proposed rule to regulate lab-developed tests will negatively impact their labs. Only 3% believe they have the financial resources to comply.
- January 25, 2024ARUP and the University of Utah Department of Pathology have announced that ARUP’s executive vice president, Julio Delgado, MD, MS, will be the inaugural holder of a new presidential endowed chair.
- December 6, 2023
Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union
ARUP and Medicover have partnered to provide a new companion diagnostic test to European Union patients. The test helps identify individuals eligible for a new gene therapy for severe hemophilia A. - December 1, 2023
ARUP Laboratories Honored With 2023 Best Companies to Work For Award From Utah Business Magazine
Utah Business magazine honored ARUP Laboratories with its Best Companies to Work For award for the sixth consecutive year based on anonymous employee survey results. - November 29, 2023
ARUP Laboratories Urges FDA to Withdraw Proposed Rule Regulating Laboratory-Developed Tests
ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight. - November 10, 2023
EU Approval of AAV5 DetectCDx™ Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy. - October 10, 2023
ARUP Healthcare Advisory Services Wins a Third ASCP Choosing Wisely Champion Award
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology. - September 29, 2023New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
- July 5, 2023
ARUP Blood Services Implements Changes in Response to New FDA Guidelines on Blood Donor Assessment
The FDA now recommends the same assessment questions for all donors, regardless of gender or sexual orientation. ARUP Blood Services is one of the first donor centers to update processes in response. - June 29, 2023ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.